<p>(A) H929 and MM.1S cells (harboring wild type p53), and (B) 8226R5 (p53 null) and U266 (p53 mutant) cell lines were treated with different concentrations of RITA for 8 hrs. (C) H929 or MM.1S cells were treated with 2.5 µM or 1 µM RITA, respectively for different time periods (4–12 hrs). The cells were then harvested and subjected to preparation of whole-cell protein lysates for detection of the indicated proteins by Western blot analysis.</p
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-...
<p>(A) The phosphorylation profile of p53 protein following MNNG treatment. TW01 and NA cells were t...
<p>(<b>A</b>) MM.1S or H929 cells were treated with RITA (1 µM for MM.1S or 2.5 µM for H929), nutlin...
<p>H929 cells were pretreated with SP600125 for 30 min (A) or transfected with scrambled or JNK siRN...
<p>RITA induces the activation of p53 through c-Jun/JNK signaling pathway by inducing phosphorylatio...
The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (MM) makes...
<div><p>The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (M...
<p>(A and B) HN30 (wild-type p53) and HN31 (mutated p53) head and neck cancer cells were treated wit...
<p>Gene expression analysis by microarray in MM.1S cells after 6 hrs treatment with 1 µM RITA. (A) S...
<p>(A) Levels of total and phosphorylated p53 and p21 were measured in HN30 and HN31 lentiviral-tran...
<p>A: Western Blot analyses after 24 h of incubation with doses of nutlin-3 (5 µM and 10 µM) and RIT...
Background and Objective: The use of low-molecular-weight, nonpeptidic molecules that degrade the in...
The first tumour-suppressor gene to be identified was p53. Reactivation of p53 and induction of tumo...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-...
<p>(A) The phosphorylation profile of p53 protein following MNNG treatment. TW01 and NA cells were t...
<p>(<b>A</b>) MM.1S or H929 cells were treated with RITA (1 µM for MM.1S or 2.5 µM for H929), nutlin...
<p>H929 cells were pretreated with SP600125 for 30 min (A) or transfected with scrambled or JNK siRN...
<p>RITA induces the activation of p53 through c-Jun/JNK signaling pathway by inducing phosphorylatio...
The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (MM) makes...
<div><p>The low frequency of p53 alterations e.g., mutations/deletions (∼10%) in multiple myeloma (M...
<p>(A and B) HN30 (wild-type p53) and HN31 (mutated p53) head and neck cancer cells were treated wit...
<p>Gene expression analysis by microarray in MM.1S cells after 6 hrs treatment with 1 µM RITA. (A) S...
<p>(A) Levels of total and phosphorylated p53 and p21 were measured in HN30 and HN31 lentiviral-tran...
<p>A: Western Blot analyses after 24 h of incubation with doses of nutlin-3 (5 µM and 10 µM) and RIT...
Background and Objective: The use of low-molecular-weight, nonpeptidic molecules that degrade the in...
The first tumour-suppressor gene to be identified was p53. Reactivation of p53 and induction of tumo...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
TP53 is the most commonly mutated gene in head and neck cancer (HNSCC), with mutations being associa...
Current therapy of medulloblastoma, the most common malignant brain tumor of childhood, achieves 40-...
<p>(A) The phosphorylation profile of p53 protein following MNNG treatment. TW01 and NA cells were t...